#fda-regulations

#fda-regulations

Federal food safety regulators warned Bimbo Bakeries USA for mislabeling allergens on their products, impacting 33 million Americans with food allergies.

RFK Jr.'s potential appointment could bring significant attention to food additive regulations and public health concerns.

Rizo Lopez Foods recalled products linked to a listeria outbreak that caused two deaths, leading to a federal court injunction against its operations.

The FDA has updated the definition of 'healthy' for packaged foods, aiming to improve consumer choices and public health.

The GRAS system allows food companies to self-determine ingredient safety, risking public health by keeping consumers unaware of potentially harmful additives.

The FDA proposes testing talc-based products for asbestos to ensure consumer safety, but does not ban talc outright.

Mushroom products in Southern California may contain misleading ingredients or dangerous compounds, risking consumer safety and well-being.

FDA updates 'healthy' food labeling to reflect current nutrition standards

New rules aim to empower consumers to find nutritious food easily

The definition of healthy now includes processed foods and previously excluded items

Many fruit snacks contain minimal real fruit, misleading consumers about their nutritional value.

Consumers deserve to easily understand food's nutritional value for informed decisions, particularly for ingredients like sugar.

Ultra-processed foods can contribute to health conditions like anxiety and cancer through associations, not causation.

FDA is considering implementing new labeling to help consumers identify healthier food choices and understand nutritional value.

RFK Jr. could significantly influence health policy if confirmed, but complicated bureaucratic structures may hinder his initiatives.

Legal challenges may arise against proposals for stricter regulations or bans on pharmaceutical advertisements due to First Amendment protections.

Concerns are raised about the impact of Robert Kennedy's policies on drug approval standards at the FDA.

Dense breast tissue significantly increases cancer risk, yet women often lack guidance on their diagnosis and next steps.

Recent FDA regulations will improve communication regarding breast density following mammograms.

Mammography facilities must notify patients about breast density to enhance early breast cancer detection starting Sep. 10, 2024.

Breast density can obscure cancer detection in mammograms, prompting the need for updated screening guidelines and communication about risks.

The surge in compounded GLP-1 drugs addresses availability but leads to regulatory issues and legal battles.

Compounding offers personalized medication options, even amidst drug shortages.

Compounding pharmacies are suing the FDA to continue producing tirzepatide imitations despite the drug's supply improving.

The FDA announced that the tirzepatide shortage has been resolved, impacting compounding pharmacies' operations.

The obscurity of a federal statute is enabling US pharmacies to flood the market with unvetted knockoffs of popular weight-loss drug Ozempic.

Covid tests may be effective past their expiration dates due to FDA extensions backed by additional manufacturer data.

Valisure, a tiny laboratory in Connecticut, has detected harmful chemicals in widely used medications, leading to product recalls and increased awareness of product safety issues.

Hims & Hers Health capitalized on weight-loss drug market trends while facing new competition from Eli Lilly's FDA-approved product offerings.

Compounded weight-loss drugs can offer a more affordable option compared to brand-name medications like Wegovy, potentially benefiting those struggling with insurance coverage and high costs.

Amish farmer Amos Miller faced legal challenges for selling unpasteurized raw milk products, without a permit, despite a loyal private customer base.

The Supreme Court is hearing controversial abortion cases post-Dobbs v. Jackson Women's Health Organization.

One case involves challenging FDA regulations on mifepristone for medication abortions, potentially impacting access to the drug.

The U.S. Supreme Court's decision prevents restrictions on nationwide access to the abortion pill mifepristone, but concerns persist over medication abortion access and FDA regulations.

The U.S. Supreme Court may change how the FDA interacts with regulated industries based on decisions regarding monitoring costs for fishing vessels.

The U.S. Supreme Court is considering the fate of the abortion pill mifepristone in a case that could have significant implications for reproductive healthcare access.

This case could potentially restrict access to medication abortion in the U.S., affecting states where abortion is legal and potentially reversing previous progress in abortion rights.

The U.S. Supreme Court will review the FDA's rejection of marketing new flavored vaping products, questioning FDA's decision-making process under the Family Smoking Prevention and Tobacco Control Act.

The FDA's 1938 law hampers the approval process for better, more effective sunscreen ingredients, blocking Americans from access to superior sun protection.

Americans may not have access to advanced sunscreens due to outdated FDA regulations.

The Supreme Court issued decisions upholding abortion access in recent cases, rejecting challenges to FDA's changes and clarifying conflicts between state and federal laws.

The Supreme Court dismissed a major abortion-related case due to lack of legal standing, preserving access to mifepristone without ruling on the case's merits.

The Supreme Court is considering FDA regulations on mifepristone.

Pre-2016 rules could limit access to medication abortion.

The Supreme Court case on mifepristone could impact FDA regulations broadly.

FDA oversight could face challenges affecting various medications and therapies.